Improving Survival for Men with Prostate Cancer by Improving Clinical Trials and Meta-Analyses
03 November 2022, 1:00 pm–2:00 pm
Professor Parmar will present how the design of the randomised clinical trial has been changed to improve outcomes for patients more quickly.
This event is free.
Book your place
About the Lecture:
Randomised clinical trials are the cornerstone of evidence-based medicine. Professor Parmar will present how the design of the randomised clinical trial has been changed to improve outcomes for patients more quickly. This will be exemplified throughout by the STAMPEDE trial. The trial was started in 2005 when men with metastatic prostate cancer had an expected survival of approximately 3 years and no new effective treatments had been identified for over 40 years. Over the subsequent 17 years, through the STAMPEDE trial (together with other contemporaneous trials) the expected survival period has grown to 7 years, testing and introducing 4 new treatments for men with this disease. Professor Parmar will show how this model is being applied worldwide to many diseases including neurodegenerative diseases such as motor neuron disease, progressive multiple sclerosis, Parkinsons disease and dementia where the outcomes for patients are poor and little or no progress has been made for decades.
This Autumn, we bring you a Lunch Hour Lecture Series to showcase how UCL research transforms lives.
About the Speaker
Professor of Medical Statistics and Epidemiology at UCL
Max Parmar is a Professor of Medical Statistics and Epidemiology and Director of both the MRC Clinical Trials Unit at UCL and the Institute of Clinical Trials and Methodology at University College London. From 2001 to 2012 he was an Associate Director of the National Cancer Research Network, an organisation which more than doubled the number of patients going into cancer studies in England. Max joined the MRC in 1987.
He has more than 400 publications in peer reviewed journals, many of which have had direct impact on policy, clinical practice and improving outcomes for patients. The Unit he directs is at the forefront of resolving internationally important questions, particularly in infectious diseases and cancer, and more recently in neuro-degenerative disease. A major aim is to deliver swifter and more effective translation of scientific research into patient benefits. It does this by carrying out challenging and innovative studies and by developing and implementing methodological advances in study design, conduct and analysis.